<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5001BA51-8FC0-4C3B-B5BC-53AC2182DD3E"><gtr:id>5001BA51-8FC0-4C3B-B5BC-53AC2182DD3E</gtr:id><gtr:firstName>Rodney</gtr:firstName><gtr:otherNames>Stuart</gtr:otherNames><gtr:surname>Daniels</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117531986"><gtr:id>BEDAF22A-4F47-485C-8AC4-D9D85A93727A</gtr:id><gtr:title>Variation of HIV genes and their encoded proteins: molecular epidemiological investigations</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117531986</gtr:grantReference><gtr:abstractText>HIV glycoproteins play a pivotal role in initiating infection and, due to the degree of variation they can tolerate, are major determinants of escape from the host immune system thereby allowing virus persistence in the infected individual. A better understanding of the structure(s) of the glycoproteins and alterations induced by specific mutations, in terms of structure and function, will allow a more defined approach to the design and development of anti-virals targeting the glycoprotein functions. Such anti-virals, in combination with others (e.g. those targeting the viral protease and reverse transcriptase) and vaccines may assist in the clearance of virus from infected individuals. On a wider basis, lessons learnt during the course of structural studies of HIV glycoproteins will be applicable to similar proteins.</gtr:abstractText><gtr:technicalSummary>HIV represents the major natural disease threat to mankind going into the 21st century. This project aims to obtain information on the structure of HIV glycoproteins and relate this to their known functions. The glycoproteins are important for initiation and spread of HIV infection and they are the only virus proteins to which neutralising antibodies are raised. A better understanding of their structure/function relationships will assist in development of anti-virals targeting the glycoprotein functions and vaccines. Due to the extent of the AIDS pandemic effective vaccines are required. |The main objective is to produce HIV glycoproteins (gp160) in sufficient quantity, quality (of good stability and maintaining, receptor binding, membrane fusion, and antigenic properties) and purity to allow structural studies by a variety of techniques including Circular Dichroism, Electron Microscopy, Nuclear Magnetic Resonance and X-ray Crystallography. The HIV glycoprotein is heavily glycosylated and a proportion of this is essential to its correct folding and subsequent functioning. This glycosylation is considered to be the major obstacle in obtaining good structural information.|Novel env-genes (see project 49828) are mutagenised to produce soluble fragments of gp160, as either the oligomeric ectodomain (gp140) or monomeric gp120 or oligomeric gp41, in eucaryotic systems (predominantly CHO cells). These products are purified using a range of techniques (e.g. lectin chromatography, gel filtration and FPLC) and assessed for functional (ELISA, BIAcore) integrity prior to structural studies. To overcome the glycosylation problem effort is being made to remove carbohydrate by enzymatic means and co-crystallisation with either sCD4 and/or Fab fragments of MAbs (both produced in house) is being attempted. Knowledge of the three dimensional structures of HIV glycoproteins in isolation and complexed with receptors and/or antibodies will allow structure-function relationships to be visualised. |The research is at the basic end of the research spectrum and many of the results emerging to date can be considered preliminary. However: (i) structural information on HIV glycoproteins will assist in anti-viral development, with obvious commercial interest; (ii) reagents generated during the course of this work will be of use in vaccine development and HIV surveillance studies, (iii) some reagents may be considered of marketable value.</gtr:technicalSummary><gtr:fund><gtr:end>2006-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1987-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>249883</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FE73DFCE-28EF-4853-98B4-6567D98C7496</gtr:id><gtr:title>Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b31587f34c13d4d8e683294e95790d"><gtr:id>d8b31587f34c13d4d8e683294e95790d</gtr:id><gtr:otherNames>Benlahrech A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>4A0FE6634FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FF0AB76-0A94-4044-BA68-E0598A838AF9</gtr:id><gtr:title>Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2a0e2247f48be893749153e34c6c772"><gtr:id>e2a0e2247f48be893749153e34c6c772</gtr:id><gtr:otherNames>Copeland KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>F0ED1B420F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11F61D0C-ADB4-46CA-9D78-8DE1EED78392</gtr:id><gtr:title>A hypothesis: the conjunction of soldiers, gas, pigs, ducks, geese and horses in northern France during the Great War provided the conditions for the emergence of the &amp;quot;Spanish&amp;quot; influenza pandemic of 1918-1919.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f941f2e3637cd1f3c2725d2a6705988"><gtr:id>0f941f2e3637cd1f3c2725d2a6705988</gtr:id><gtr:otherNames>Oxford JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>4D5ECBF9EFB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4C12B53-384F-4053-A0CA-240A56F13535</gtr:id><gtr:title>CD4 binding affinity determines human immunodeficiency virus type 1-induced alpha interferon production in plasmacytoid dendritic cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84c81e5aebded304feb766875e1889a6"><gtr:id>84c81e5aebded304feb766875e1889a6</gtr:id><gtr:otherNames>Haupt S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>CB70CAFB686</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117531986</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>